BofA raised the firm’s price target on Cardinal Health (CAH) to $170 from $165 and keeps a Buy rating on the shares ahead of the company’s upcoming investor day on June 12. Expectations are high heading into the event due to “impressive execution over the past two years and multiple industry tailwinds,” says the analyst, who increases the firm’s target to reflect higher peer multiples. The firm expects Cardinal Health to raise its long-term target Pharmaceutical EBIT growth guidance from 4-6% to 5-7% or 5-8%, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Citius Oncology enters distribution services agreement with Cardinal Health
- Cardinal Health, Dollar General, Snowflake, Constellation, and CrowdStrike: Trending by Analysts
- Cardinal Health announces U.S. launch of its new Kendall DL Multi System
- Reddit initiated, Pinterest upgraded: Wall Street’s top analyst calls
- Wells Fargo upgrades Cardinal Health to Overweight, raises target to $179